Follow
Tina Nassehi
Title
Cited by
Cited by
Year
BCL11A enhancer–edited hematopoietic stem cells persist in rhesus monkeys without toxicity
S Demirci, J Zeng, Y Wu, N Uchida, AH Shen, D Pellin, J Gamer, ...
The Journal of clinical investigation 130 (12), 6677-6687, 2020
562020
High-efficiency lentiviral transduction of human CD34+ cells in high-density culture with poloxamer and prostaglandin E2
N Uchida, T Nassehi, CM Drysdale, J Gamer, M Yapundich, S Demirci, ...
Molecular Therapy-Methods & Clinical Development 13, 187-196, 2019
412019
Cas9 protein delivery non-integrating lentiviral vectors for gene correction in sickle cell disease
N Uchida, CM Drysdale, T Nassehi, J Gamer, M Yapundich, J DiNicola, ...
Molecular Therapy-Methods & Clinical Development 21, 121-132, 2021
312021
Busulfan combined with immunosuppression allows efficient engraftment of gene-modified cells in a rhesus macaque model
N Uchida, T Nassehi, CM Drysdale, J Gamer, M Yapundich, ...
Molecular Therapy 27 (9), 1586-1596, 2019
292019
Hematopoietic stem cell-targeted gene-addition and gene-editing strategies for β-hemoglobinopathies
CM Drysdale, T Nassehi, J Gamer, M Yapundich, JF Tisdale, N Uchida
Cell Stem Cell 28 (2), 191-208, 2021
242021
Preclinical evaluation for engraftment of CD34+ cells gene-edited at the sickle cell disease locus in xenograft mouse and non-human primate models
N Uchida, L Li, T Nassehi, CM Drysdale, M Yapundich, J Gamer, ...
Cell Reports Medicine 2 (4), 2021
232021
Low-dose busulfan reduces human CD34+ cell doses required for engraftment in c-kit mutant immunodeficient mice
A Leonard, M Yapundich, T Nassehi, J Gamer, CM Drysdale, ...
Molecular Therapy-Methods & Clinical Development 15, 430-437, 2019
232019
βT87Q-globin gene therapy reduces sickle hemoglobin production, allowing for ex vivo anti-sickling activity in human erythroid cells
S Demirci, B Gudmundsdottir, Q Li, JJ Haro-Mora, T Nassehi, C Drysdale, ...
Molecular Therapy Methods & Clinical Development 17, 912-921, 2020
152020
Sustained fetal hemoglobin induction in vivo is achieved by BCL11A interference and coexpressed truncated erythropoietin receptor
N Uchida, F Ferrara, CM Drysdale, M Yapundich, J Gamer, T Nassehi, ...
Science Translational Medicine 13 (591), eabb0411, 2021
82021
Durable and robust fetal globin induction without Anemia in rhesus monkeys following autologous hematopoietic stem cell transplant with BCL11A Erythroid enhancer editing
S Demirci, J Zeng, Y Wu, N Uchida, J Gamer, M Yapundich, C Drysdale, ...
Blood 134, 4632, 2019
52019
Fetal hemoglobin and F-cell variance in mobilized CD34+ cell-transplanted rhesus monkeys
S Demirci, JJH Mora, M Yapundich, C Drysdale, J Gamer, T Nassehi, ...
Experimental hematology 75, 21-25. e1, 2019
42019
Ex vivo immunological evaluation of stable mixed chimeric patients after matched related donor allogeneic transplantation in sickle cell disease
LN Raines, MM Hsieh, T Nassehi, CM Drysdale, JF Tisdale, N Uchida
Cytotherapy 21 (12), 1206-1215, 2019
32019
Preclinical evaluation for engraftment of gene-edited CD34+ cells with a sickle cell disease mutation in a rhesus transplantation model
N Uchida, L Li, T Nassehi, M Yapundich, J Gamer, C Drysdale, ...
Blood 134, 609, 2019
32019
Development of Cas9 protein delivery non-integrating lentiviral vectors for gene correction in sickle cell disease
N Uchida, T Nassehi, CM Drysdale, J Gamer, M Yapundich, S Demirci, ...
Molecular Therapy 28 (4), 395-396, 2020
22020
Truncated erythropoietin receptors confer an in vivo selective advantage in gene-modified erythroid cells expressing fetal hemoglobin due to bcl11a interference
N Uchida, C Drysdale, M Yapundich, J Gamer, T Nassehi, M Wielgosz, ...
Blood 134, 2063, 2019
22019
Development of a clinically applicable method for high-efficiency gene correction of plerixafor-mobilized CD34+ cells from patients with sickle cell disease
N Uchida, L Li, JJ Haro-Mora, S Demirci, T Nassehi, J Gamer, C Drysdale, ...
Blood 132, 2191, 2018
22018
Durable robust fetal globin induction in rhesus monkeys following BCL11A erythroid enhancer edited autologous hematopoietic stem cell transplant
S Demirci, J Zeng, Y Wu, N Uchida, J Gamer, M Yapundich, C Drysdale, ...
MOLECULAR THERAPY 28 (4), 241-242, 2020
12020
Engraftability of gene-edited sickle cell disease CD34+ cells in xenograft mouse and rhesus transplantation models
N Uchida, L Li, T Nassehi, M Yapundich, J Gamer, C Drysdale, ...
MOLECULAR THERAPY 28 (4), 175-175, 2020
12020
Let us know how access to this document benefits you.
S Demirci, J Zeng, Y Wu, N Uchida, AH Shen, D Pellin, J Gamer, ...
2020
High-Efficiency Lentiviral Transduction of Human CD34+ Cells in High-Density Cell Culture with Poloxamer and Prostaglandin E2 Supplementation
N Uchida, T Nassehi, CM Drysdale, J Gamer, M Yapundich, S Demirci, ...
MOLECULAR THERAPY 27 (4), 325-325, 2019
2019
The system can't perform the operation now. Try again later.
Articles 1–20